LEEDS, England, May 13 /PRNewswire/ -- In a bid to help alleviate the current "demographic timebomb" facing pharmacy in the UK, Teva UK Limited, the UK's leading generics manufacturer, is launching a Student Bursary Scheme.
The company is a keen supporter of pharmacy in the UK, and already has several initiatives in place to help pharmacists make the most of their role in the ever-changing UK healthcare climate. And now it's extending this support to include the pharmacists of the future. The Student Bursary will be available to students who want to gain a degree-level qualification in pharmacy or similar but may suffer hardship without additional financial support.
Teva's UK HR Director, Lynda Wilebore, said: "We're delighted to be able to introduce the Student Bursary Scheme, which we hope will make an important contribution to lives of under-privileged students in the UK."
She added: "We believe it is important to have a community support programme that is relevant to our business. As the UK's leading generics company, we're totally committed to pharmacy in the UK. This means we're not only interested in supporting the pharmacists of today, but also in ensuring the pharmacists of tomorrow get the best possible start."
The Student Bursary Scheme is open to any home UK student who is either already attending, or who has been offered a place on, any full-time UK-based undergraduate course approved by a school of pharmacy or similar. Each year, bursaries will be offered to students who may suffer difficulty without additional financial support. The company especially welcomes applications from A-level students who receive the Education Maintenance Allowance or Carers Allowance. Up to ten bursaries will be awarded each year, comprising GBP500 payment for each year of study. The closing date for the next round of applications is 1 September 2008.
For further information, including an information pack, how to apply and selection criteria, please contact the HR department - email firstname.lastname@example.org or telephone +44(0)8705-020304. Alternatively, visit http://www.tevauk.com/careers/bursary. The closing date for the next round applications is 1 September 2008.
Notes to Editors:
Teva UK Limited is one of the UK's leading pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. With over 500 product lines, it has the widest range of any UK generic pharmaceutical company and has a number of innovative respiratory products including the Qvar(R) (beclometasone dipropionate) CFC-free inhaler.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(R), Neurontin(R), Lotrel(R), and Famvir(R), the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Media enquiries: Philippa Ward, Communications & PR Officer, +44(0)113-201-3972